Related Experiment Videos
Phase II study of paclitaxel and cisplatin for advanced urothelial cancer
P A Burch1, R L Richardson, S S Cha
1Division of Medical Oncology, Department of Biostatistics, Mayo Foundation, Rochester, Minnesota, USA.
Purpose:
We examined the role of paclitaxel and cisplatin as first line therapy for metastatic urothelial cancer.
Materials And Methods:
A total of 34 patients were enrolled in this study, and all were eligible for treatment and assessable for response. Patients received 135 mg./m.2 paclitaxel intravenously for 3 hours followed by 70 mg./m.2 cisplatin for 2 hours every 3 weeks to a maximum of 6 cycles.
Results:
Of the patients 70% experienced a major response to treatment, which was partial/regression in 38% and complete in 32%. Toxicity was manageable with no episodes of grade 4 leukopenia or thrombocytopenia. Nonhematological toxicities included primarily nausea, anorexia and neuropathy, which rarely were severe.
Conclusions:
This regimen of paclitaxel and cisplatin is effective, safe and convenient to administer in an outpatient setting for advanced urothelial cancer.